Physician profile
April Riley
NPI 1629489885
$2,053.81
in general payments reported to CMS, 2019-2025
26 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2021: $28.90 · 2022: $643 · 2023: $720 · 2024: $419 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.50 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.06 | 2021-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Mimedx Group, INC. | $200.00 | 2024 | |
| Exeltis, USA INC. | $141.57 | 2022-2025 | Slynd |
| Organon LLC | $128.59 | 2022-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $128.04 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $124.19 | 2023-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $123.83 | 2019 | |
| Agile Therapeutics, INC. | $123.14 | 2022-2024 | Twirla |
| Pfizer INC. | $94.82 | 2022-2025 | |
| Hologic Sales and Service, LLC | $94.06 | 2022 | |
| Mayne Pharma Commercial LLC | $91.69 | 2022-2025 | |
| Caldera Medical, INC | $82.02 | 2022 | |
| Axonics, INC. | $63.64 | 2023-2024 | Bulkamid |
| Myovant Sciences INC. | $44.80 | 2022 | |
| Aspira Women'S Health INC | $36.62 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $35.18 | 2023 | Irrisept |
| Minerva Surgical, INC | $25.97 | 2024 | |
| Meditrina | $20.47 | 2023 | |
| Millicent US INC | $19.59 | 2023 | Intrarosa |
| Dexcom, INC. | $19.37 | 2025 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $18.68 | 2022 | |
| Sage Therapeutics, LLC | $18.12 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $16.20 | 2022 | |
| Heron Therapeutics, INC. | $14.64 | 2024 | Zynrelef |
| Avion Pharmaceuticals | $13.69 | 2023 | Balcoltra |
| Coopersurgical, INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.